4577 Pharmaceuticals

Vifor Pharma Ltd. Monitor

Vifor Pharma Ltd. Annual Report 2018
CR Monitor Issue: 
2019/0421
Company covered: 
Vifor Pharma Ltd.
Period End: 
31 December, 2018
Report issued on 26 April 2019 covered the following practice issues:
Pronouncements
Restatement of financial statement due to the adoption of IFRS 15 Revenue from contracts with customers.
Pronouncements
Disclosure in respect of the impact of IFRS 9 Financial instruments.
Pronouncements
Additional disclosure in respect of the expected impact of the new standard IFRS 16 Leases.
Change
Disclosure of a new share-based payment plan.
Change
Additional disclosure in respect of a review of actuarial assumptions.

Dechra Pharmaceuticals plc Monitor

Dechra Pharmaceuticals plc Annual Report 2018
CR Monitor Issue: 
2019/0115
Company covered: 
Dechra Pharmaceuticals plc
Period End: 
30 June, 2018
Report issued on 22 January 2019 covered the following practice issues:
Pronouncements
Disclosure in respect of the expected impact of new accounting standards including IFRS 9 "Financial instruments", IFRS 15 "Revenue from contracts with customers” and IFRS 16 “Leases”.
Change
Discussion of key audit matters included in the audit report including identification of a new key audit matter.
Change
Deferred tax changes recognised following changes to US tax legislation.
Change
Change in allocation of goodwill to cash generating units for impairment test purposes.
Change
Disclosure regarding remeasurement of contingent consideration.

Roche Holding Ltd Monitor

Roche Holding Ltd Annual Report 2017
CR Monitor Issue: 
2018/0521
Company covered: 
Roche Holding Ltd
Period End: 
31st December 2017
Report issued on 29 May 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of the future impacts of new accounting standards.
Change
Additional information disclosed in respect of provisions.
Change
Disclosure of IFRS 5 information linked to business disposals.
Change
Change in presentation of cash flows from investing activities.
Change
Calculation of goodwill linked to step acquisitions takes into account fair value of previously held interests.
Change
Newly acquired investment in associate accounted for using the equity method.

GlaxoSmithKline plc Monitor

GlaxoSmithKline plc Annual Report 2017
CR Monitor Issue: 
2018/0508
Company covered: 
GlaxoSmithKline plc
Period End: 
31 December, 2017
Report issued on 08 May 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of the future impacts of new accounting standards including quantification.
Change
Expanded disclosure of Non IFRS performance measures.
Change
Extended disclosure of principal risks including identification of new risk factor.
Change
Change in calculation of segment profit results in restatement of prior year figures.
Change
Change in disclosure in audit report in respect of director and auditor responsibilities.

Merck KGaA Monitor

Merck KGaA Annual Report 2017
CR Monitor Issue: 
2018/0415
Company covered: 
Merck KGaA
Period End: 
31 December, 2017
Report issued on 16 April 2018 covered the following practice issues:
Restatement
Finalisation of prior year provisional business combination amounts.
Pronouncements
Disclosure of the future impacts of new standards yet to be adopted including IFRS 9 "Financial instruments" and IFRS 15 "Revenue from contracts with customers".
Change
Audit report enhanced by inclusion of key audit matters.
Change
Segment disclosures extended.

Novo Nordisk A/S Monitor

Novo Nordisk A/S Annual Report Year
CR Monitor Issue: 
2018/0307
Company covered: 
Novo Nordisk A/S
Period End: 
31 December, 2017
Report issued on 13 March 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of new accounting standards issued but not yet effective including IFRS 9, IFRS 15 and IFRS 16.
Change
Structure of geographic segment information altered.
Change
Additional disclosure in respect of research and development milestone payments
New
Disclosure of social accounting policies extended.

GlaxoSmithKline plc Monitor

GlaxoSmithKline plc Annual Report 2016
CR Monitor Issue: 
2017/0811
Company covered: 
GlaxoSmithKline plc
Period End: 
31 December, 2016
Report issued on 22 August 2017 covered the following practice issues:
Restatement
Change in composition of reporting segments linked to restructuring of the business.
Change
Identification of new areas of audit focus in relation to "Acquisition-related liabilities" and "Finance transformation".
Pronouncements
Disclosure of proposed changes in non-audit services policy in line with Financial Reporting Council’s (FRC’s) revised Ethical Standards and new EU Audit Regulation.
Pronouncements
IFRIC interpretation leads to change in presentation in respect of cash pooling arrangements.
Restatement
Analysis of defined benefit scheme assets and obligations restated to exclude defined contribution plan amounts.

Novartis AG Monitor

Novartis AG Annual Report 2016
CR Monitor Issue: 
2017/0402
Company covered: 
Novartis AG
Period End: 
31 December, 2016
Report issued on 04 April 2017 covered the following practice issues:
Change
Change in segment disclosure to reflect changes in organisational structure.
Pronouncements
Introduction to audit report of a table disclosing key audit matters.
Change
Presentation of additional income statement, statement of changes in equity and cash flow statement comparative information.

AstraZeneca plc Monitor

AstraZeneca plc Annual Report 2015
CR Monitor Issue: 
2016/0911
Company covered: 
AstraZeneca plc
Period End: 
31 December, 2015
Report issued on 27 September 2016 covered the following practice issues:
Change
Redefinition of what is considered revenue with the reclassification of externalisation income from other operating income to revenue.

Roche Holding Ltd Monitor

Roche Holding Ltd Annual Report 2015
CR Monitor Issue: 
2016/0901
Company covered: 
Roche Holding Ltd
Period End: 
31 December, 2015
Report issued on 07 September 2016 covered the following practice issues:
Change
Finalisation of the accounting of business acquisition resulting in decrease to goodwill.
New
Recognition of restructuring costs including loss on divestment.